ZEAL: Major clinical data for petrelintide and Survodutide will define a transformative year in metabolic health – TradingView Track All Markets

Ambitious plans target obesity and metabolic diseases, with major clinical milestones for petrelintide and Survodutide expected in 2024. Strategic partnerships with Roche and Boehringer Ingelheim support a robust pipeline, aiming for five product launches in five years and significant investment in …

Source: TradingView Track All Markets

Read More